QuidelOrtho shares dropped 21% in after‑hours trading after issuing Q1 2026 revenue guidance of $615‑$620 million, below consensus $679.6 million.
Company cited a 30% decline in U.S. influenza‑like illness visits, slower China distributor sales due to proposed reimbursement cuts, and order delays in EMEA from the Middle East conflict.
Forecasted Q1 2026 free cash flow of –$65 million to –$70 million, maintaining a full‑year positive cash‑flow outlook while launching cost‑reduction measures.
CEO Brian J. Blaser said core business (>70% of revenue) stays strong; full Q1 results to be released May 5 2026 after market close.